Overview

mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This phase Ⅱ study was designed to evaluate the efficacy and safety of mFOLFIRINOX as first-line treatment for metastatic pancreatic cancer in China.
Phase:
Phase 2
Details
Lead Sponsor:
Yuhong Li
Treatments:
Irinotecan
Leucovorin
Oxaliplatin